Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.530
+0.170 (7.20%)
At close: Feb 6, 2026, 4:00 PM EST
2.548
+0.018 (0.73%)
After-hours: Feb 6, 2026, 7:59 PM EST
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 838 employees as of December 31, 2024. The number of employees increased by 281 or 50.45% compared to the previous year.
Employees
838
Change (1Y)
281
Growth (1Y)
50.45%
Revenue / Employee
$298,837
Profits / Employee
-$474,502
Market Cap
1.00B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 838 | 281 | 50.45% |
| Dec 31, 2023 | 557 | 54 | 10.74% |
| Dec 31, 2022 | 503 | 184 | 57.68% |
| Dec 31, 2021 | 319 | 78 | 32.37% |
| Dec 31, 2020 | 241 | 93 | 62.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Phathom Pharmaceuticals | 427 |
| Vir Biotechnology | 408 |
| UroGen Pharma | 287 |
| Geron | 229 |
| ARS Pharmaceuticals | 167 |
| ORIC Pharmaceuticals | 106 |
| Nanobiotix | 103 |
| Theravance Biopharma | 97 |
IOVA News
- 1 day ago - Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma - GlobeNewsWire
- 21 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Iovance Biotherapeutics: Bright Prospects For 2026 - Seeking Alpha
- 3 months ago - Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode - Seeking Alpha
- 3 months ago - Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders - GlobeNewsWire
- 4 months ago - Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play - Seeking Alpha
- 5 months ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire